Original paper
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Abstract
Ingrowth of newly formed blood and lymph vessels (angiogenesis) from the limbus region into the cornea can be treated successfully by subconjunctival application of antiangiogenic agents. Currently, there are several angiogenesis inhibitors from various manufacturers available, such as vascular endothelial growth factor (VEGF) antibodies. The aim of the study was to investigate potential cytotoxic effects of two anti-VEGF agents, ranibizumab...
Paper Details
Title
Effects of ranibizumab (Lucentis®) and bevacizumab (Avastin®) on human corneal endothelial cells
Published Date
Dec 1, 2018
Journal
Volume
18
Issue
1
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History